Emergent BioSolutions Reports Financial Results for 2006

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that total revenues for 2006 grew 17 percent to $152.7 million from $130.7 million in 2005, driven by the delivery of over 6 million doses of BioThrax® (Anthrax Vaccine Adsorbed) during the year to the U.S. Department of Health and Human Services (HHS) for inclusion in the strategic national stockpile and to the U.S. Department of Defense (DoD) for use in DoD’s active immunization program.

Back to news